RANZCR invites stakeholder consultation on newly developed guidelines addressing patient consent for Artificial Intelligence (AI) applications in clinical practice. As AI systems become increasingly embedded in medical imaging and treatment planning, these guidelines provide essential safeguards to ensure ethical implementation.
The guidelines advocate maintaining meaningful human control. It establishes tiered consent processes based on the potential impact of the AI tool, with particular attention to systems that directly influence diagnosis or treatment pathways. The guidelines recognise AI's potential to enhance care delivery while establishing necessary boundaries to protect patient safety and consent.
This consultation represents an important opportunity for stakeholders to shape the responsible adoption of AI in healthcare.
Submissions will be accepted until 24 September 2025, with final guidelines anticipated for publication in December 2025.
Documentation: Patient consent for the use of AI in clinical radiology and radiation oncology
For further information, or to submit your feedback, please contact This email address is being protected from spambots. You need JavaScript enabled to view it., referencing line numbers where appropriate.
Overview
RANZCR invites stakeholder consultation on a new advocacy paper supporting the role of brachytherapy in cancer care.
Brachytherapy delivers targeted radiation directly to tumours, minimising exposure to surrounding healthy tissue. It is an essential treatment for cancers such as gynaecological and prostate tumours, and evidence suggests it may also benefit other tumour types, particularly in paediatric cases.
Despite its proven value, access to brachytherapy in Australia has plateaued in recent years. The cessation of Radiation Oncology Health Program Grant (ROHPG) funding has contributed to service declines, especially in regional and private settings, raising concerns about long-term access, workforce capacity, and sustainability.
This consultation provides an important opportunity for stakeholders to shape solutions that will safeguard the availability of brachytherapy for patients who need it most.
Submissions will be accepted until 15 October 2025.
Specialty
Radiation Oncology
How to submit
Please send through your comments and feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. by COB 15 October 2025. Please reference line numbers where appropriate.
Relevant documentation
Brachytherapy: An essential radiation therapy modality for optimising patient care [View document here]